Characterization of YY1 OPB Peptide for Its Anticancer Activity.

Characterization of YY1 OPB Peptide for Its Anticancer Activity. Curr Cancer Drug Targets. 2018 Oct 31;: Authors: Qi Y, Yan T, Chen L, Zhang Q, Wang W, Han X, Li D, Shi J, Sui G Abstract The oncoprotein binding (OPB) domain of Yin Yang 1 (YY1) consists of 26 amino acids between G201 and S226, and is involved in YY1 interaction with multiple oncogene products, including MDM2, AKT, EZH2 and E1A. Through the OPB domain, YY1 promotes the oncogenic or proliferative regulation of these oncoproteins in cancer cells. We previously demonstrated that a peptide with the OPB sequence blocked YY1-AKT interaction and inhibited breast cancer cell proliferation. In the current study, we characterized the OPB domain and determined a minimal region for peptide design to suppress cancer cells. Using alanine-scan method, we identified that the amino acids at OPB C-terminal are essential to YY1 binding to AKT. Further studies suggested that serine and threonine residues, but not lysines, in OPB play a key role in YY1-AKT interaction. We generated GFP fusion expression vectors to express OPB peptides with serially deleted N-terminal and found that OPB1 (i.e. G201-S226) is cytoplasmic, but OPB2 (i.e. E206-S226), OPB3 (i.e. E206-S226) and control peptide were both nuclear and cytoplasmic. Both OPB1 and 2 inhibited breast cancer cell proliferation and migration, but OPB3 exhibited similar effects to control. OPB1 and 2 caused cell cycle arrest at G1 phase, increased p53 and p21 ...
Source: Current Cancer Drug Targets - Category: Cancer & Oncology Authors: Tags: Curr Cancer Drug Targets Source Type: research

Related Links:

ConclusionIn breast cancer, D and f values show significant differences according to TSR, and D value is lower in collagen dominant type than in fibroblast dominant or lymphocyte dominant types.
Source: European Journal of Radiology - Category: Radiology Source Type: research
ConclusionConventional BC-imaging modalities have both advantages and limitations. When utilized in combination, they are often complementary. For example, a limitation of mammography is low sensitivity in dense breasts. The addition of DBT lessens this limitation by providing three-dimensional (3D) images of the breast that minimizes the effect of overlying breast tissue. Additionally, US added to mammography in dense breasts increases screening sensitivity and has the advantages of accessibility and lack of ionizing radiation. MRI is currently the most sensitive method used for detecting BC. When MRI is not suitable for ...
Source: Clinical and Translational Imaging - Category: Radiology Source Type: research
This 61-year-old woman presented with new primary triple negative breast cancer (TNBC) in the lateral breast 10 years after completing radiation for ductal carcinoma in situ (DCIS) in the same breast.1 Despite neoadjuvant chemotherapy and mastectomy with only residual DCIS and negative nodes, patient developed a TNBC re-recurrence only 9 months later. She was treated with chemotherapy, and there remains positive residual localized disease by positron emission tomography (PET). At this point we recommend the following.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Gray Zone Source Type: research
Although we report an increased rate of grade (G) 2 or greater radiation dermatitis (RD), predominantly driven by G2 toxicity, we do not describe a doubling in the overall rate of RD seen in patients with breast cancer undergoing adjuvant proton pencil-beam scanning (PBT). We advise counseling patients of the potential for increased dermatologic toxicity, though this should not affect modality selection, considering a very low number of patients experienced G3 to G4 RD.1Although it is notable that this increased toxicity occurs in the absence of bolus, we do not conclude that PBT should be used in lieu of photon radiation ...
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Comment Source Type: research
ConclusionsBoth 18F-HX4 and 18F-FMISO PET/CT can be used as biomarkers for tumor hypoxia and radiotherapy-associated changes. The clinical utilization of these two PET tracers needs to be further validated.
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 13 September 2019Source: Life SciencesAuthor(s): Sajjad Ahmadpour, Seyed Jalal HosseinimehrAbstractBreast cancer deaths occur mainly because of poor diagnosis in early stages that lead to tumor metastasis in advanced stages. Developing a high-sensitive early-stage breast cancer diagnostic tool based on single photon emission computer tomography (SPECT) and positron emission tomography (PET) are urgent. There are several evidences to demonstrate the prominent roles of specific receptors overexpression in tumor initiation and progression of breast cancer. Targeting of specific receptor with...
Source: Life Sciences - Category: Biology Source Type: research
This study investigated the relationship between stromal tumor-infiltrating lymphocytes (TILs) and maximum standardized uptake value (SUVmax) in WBPET and DbPET.MethodsA total of 125 invasive breast cancers underwent WBPET and ring-type DbPET and resected specimens were pathologically assessed. The impact of SUVmax on the tumor biological parameters and TILs was retrospectively evaluated. SUVmax was classified as high and low relative to the median values (WBPET-SUVmax: 2.2 and DbPET-SUVmax: 6.0).ResultsSUVmax correlated with tumor size, nuclear grade, Ki-67 labeling index, and TILs in both WBPET and DbPET (allp 
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Objective To evaluate metabolic and volume-based parameters of 18-Fluorodeoxyglucose positron emission tomography/computed tomography ((18F)FDG PET/CT) for primary mass and axillary lymph node (ALN) metastasis in relation to molecular subtype, and immunohistochemistry and inflammatory markers in patients with invasive ductal carcinoma. Methods A total of 129 patients (mean±SD age: 49.2±13.0 years) with invasive ductal breast cancer who had (18F)FDG PET/CT imaging prior to chemotherapy or surgery were included in this single-center retrospective study. Data on patient age, molecular subtype, ALN metastasi...
Source: Nuclear Medicine Communications - Category: Nuclear Medicine Tags: Original Articles Source Type: research
Conclusion The use of new semiquantitative PET parameters may increase the diagnostic yield of FDG PET in the case of abnormal incidental 18F-FDG accumulations.
Source: Nuclear Medicine Communications - Category: Nuclear Medicine Tags: Original Articles Source Type: research
CONCLUSIONS: Both 18F-HX4 and 18F-FMISO PET/CT can be used as biomarkers for tumor hypoxia and radiotherapy-associated changes. The clinical utilization of these two PET tracers needs to be further validated. PMID: 31526971 [PubMed - as supplied by publisher]
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - Category: Drugs & Pharmacology Authors: Tags: Biomed Pharmacother Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | PET Scan | Study